11 Apr 2018 07:00
Collagen Solutions Plc
(the "Company")
Director/PDMR Dealing
The Company announces that it was notified on 10 April that David Evans, Chairman of the Company, has purchased 3,142,857 ordinary shares in the Company ("Ordinary Shares") at 2.75 pence per Ordinary Share.
Following the transaction, David Evans' total beneficial holding in the Company has increased to 42,537,411 Ordinary Shares representing 13.11 per cent. of the issued ordinary share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| David Evans
| ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chairman
| ||||
b)
| Initial notification /Amendment
| Initial | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Collagen Solutions plc | ||||
b)
| LEI
| 213800IFY1CVGRGETL95 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary shares of 1p each
ISIN: GB00B94T6Y14
| ||||
b)
| Nature of the transaction
| Purchase of shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
|
N/A - single transaction
| ||||
e)
| Date of the transaction
| 10 April 2018 | ||||
f)
| Place of the transaction
| London Stock Exchange | ||||
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For additional information on Collagen Solutions, please visit: www.collagensolutions.com
Enquiries:
Collagen Solutions Plc | Contact via Lisa Baderoon | ||
Jamal Rushdy, Chief Executive Officer |
| ||
Hilary Spence, Chief Financial Officer Lisa Baderoon, Head of Investor Relations |
Tel: +44 (0) 7721 413 496 or lisa.baderoon@collagensolutions.com | ||
|
| ||
Cenkos Securities plc (Nominated Adviser and Broker) Stephen Keys Steve Cox Callum Davidson | Tel: 0207 397 8900
| ||
|
| ||
Walbrook PR | Tel: 020 7933 8780 or collagen@walbrookpr.com | ||
Anna Dunphy | Mob: 07876 741 001 | ||
Helen Cresswell |
| ||